Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumours

Official Title

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumours

Summary:

This study is an open-label, international, multi-centre, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumours, which harbor the NRG1 gene fusion.

Trial Description

Primary Outcome:

• Objective Response Rate

View this trial on ClinicalTrials.gov